PHAT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Phathom Pharmaceuticals (PHAT) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company has strong growth potential, impressive financial performance, and positive analyst sentiment, making it a suitable choice for long-term investment.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 72.402, suggesting no overbought or oversold conditions. Moving averages are converging, showing no clear trend. Key resistance levels are at 13.79 and 14.59, with support at 11.2 and 10.4.
Strong Q4 2025 revenue growth of 94.09% YoY, with sequential growth of 16%.
Positive revenue guidance for 2026 between $320M-$345M.
Successful equity offering of $130M and reduced loan interest rate.
Total prescriptions for VOQUEZNA surpassed 1.1 million, with a 21% QoQ increase in Q
Analysts have initiated coverage with strong buy ratings and attractive price targets.
Pre-market price drop of -1.18%.
Net income dropped to 0 in Q4 2025, reflecting a lack of profitability.
Gross margin slightly declined by -0.48% YoY.
In Q4 2025, revenue increased by 94.09% YoY to $57.57M. Net income dropped to 0, but EPS improved by 188.57% YoY to -3.03. The company expects operational profitability in 2026 and cash flow positivity by 2027.
Raymond James initiated coverage with a Strong Buy rating and a $28 price target, citing the company's innovative product and expense rationalization. Barclays initiated coverage with an Equal Weight rating and a $16 price target, noting sector-wide improvements and opportunities despite a transitional phase.
